Anzeige
Meldung des Tages: Bestätigung auf Weltklasseniveau: Globale Bergbaugiganten setzen voll auf Toodoggone

Immatics News

Aktie
WKN:  A2P72S ISIN:  NL0015285941 US-Symbol:  IMTX Branche:  Biotechnologie Land:  Deutschland
9,82 €
+0,15 €
+1,55%
08:21:38 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,06 Mrd. €
Streubesitz
0,12%
KGV
-
Index-Zuordnung
-

Immatics News

21.04.26 - GlobeNewswire
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple ...
17.04.26 - GlobeNewswire
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered ...
05.03.26 - GlobeNewswire
Immatics Announces Full Year 2025 Financial Results and Business Update
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-...
11.12.25 - GlobeNewswire
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
IMA203CD8 is a second-​generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalation Manageable tolerability across all dose levels ...
05.12.25 - GlobeNewswire
Immatics Announces $125 Million Underwritten Offering
Houston, Texas and Tuebingen, Germany,  December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-​stage biopharmaceutical company and the ...
17.11.25 - GlobeNewswire
Immatics Announces Third Quarter 2025 Financial Results and Business Update
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; ...
12.11.25 - GlobeNewswire
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps  
Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET
27.10.25 - GlobeNewswire
Immatics Appoints Amie Krause as Chief People Officer
Houston , Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-​stage biopharmaceutical company and the global ...
20.10.25 - GlobeNewswire
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show ...
01.10.25 - GlobeNewswire
Immatics Appoints Venkat Ramanan as Chief Financial Officer
Houston , Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-​stage biopharmaceutical company and the global ...
13.08.25 - GlobeNewswire
Immatics Announces Second Quarter 2025 Financial Results and Business Update
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-​tumor activity and durability in 33 ...
31.05.25 - GlobeNewswire
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising ...
13.05.25 - GlobeNewswire
Immatics Announces First Quarter 2025 Financial Results and Business Update
IMA203 PRAME Cell Therapy: Randomized-​controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026 ...

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »